Home » Stocks » REGN

Regeneron Pharmaceuticals, Inc. (REGN)

Stock Price: $492.45 USD -6.39 (-1.28%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $491.91 -0.54 (-0.11%) Dec 4, 5:48 PM

REGN Stock Price Chart

Key Info

Market Cap 51.64B
Revenue (ttm) 8.24B
Net Income (ttm) 3.16B
Shares Out 105.50M
EPS (ttm) 27.29
PE Ratio 18.05
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $492.45
Previous Close $498.84
Change ($) -6.39
Change (%) -1.28%
Day's Open 497.01
Day's Range 490.06 - 501.85
Day's Volume 960,047
52-Week Range 336.18 - 658.21

REGN Stock News

Forbes - 1 day ago

While Regeneron stock is up 38% since the start of the year, it has dropped around 20% from its July highs of around $660. After the recent decline, REGN stock could offer an upside in the nea...

Business Wire - 2 days ago

NEW YORK--(BUSINESS WIRE)-- #REGN--Scott+Scott Continues Investigation of Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty – REGN

Seeking Alpha - 2 days ago

Regeneron Pharmaceuticals' (REGN) Management Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference (Transcript)

Seeking Alpha - 3 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Evercore ISI 3rd Annual HealthCONx Conference (Transcript)

InvestorPlace - 3 days ago

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks invest...

Other stocks mentioned: ABBV, INO, NVAX
Zacks Investment Research - 4 days ago

Regeneron (REGN) and Sanofi win EC nod for Dupixent for the indication of severe atopic dermatitis in children 6 to 11 years of age.

Other stocks mentioned: SNY
PRNewsWire - 4 days ago

TARRYTOWN, N.Y., Nov. 30, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a webcast on Monday, December 7, 2020 at 4:30pm EST. Management will discuss data presen...

Zacks Investment Research - 1 week ago

Let's see if Regeneron Pharmaceuticals (REGN) stock is a good choice for value-oriented investors right now from multiple angles.

24/7 Wall Street - 1 week ago

The short interest data are out for November 13, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big p...

Other stocks mentioned: ALXN, AMGN, BIIB, GILD, MRNA, VRTX
Zacks Investment Research - 1 week ago

Regeneron's (REGN) antibody cocktail gets Emergency Use Authorization by the FDA for the treatment of COVID-19.

InvestorPlace - 1 week ago

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here's how this affects other Covid-19-related biotech stocks. The post 7 Biotech Stocks That Are Locked in the Race ...

Other stocks mentioned: ABT, AZN, GILD, INO, JNJ, NVAX, SRNE
Yahoo Finance - 1 week ago

Coronavirus vaccine: Breaking down Astrazenca's trial efficacy and Regeneron's antibody

Yahoo Finance's Anjalee Khemlani breaks down the latest in vaccine and and antibody treatments. #coronavirus #COVID19 #coronavirusvaccine Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb Ab...

Other stocks mentioned: AZN
24/7 Wall Street - 1 week ago

A COVID-19 vaccine appears to be just around the corner, and many of the companies developing drugs, cocktails, vaccines and treatments are very close to crossing the finish line.

Other stocks mentioned: AZN, BNTX, GILD, LLY, MRNA, PFE
InvestorPlace - 1 week ago

REGN stock is shifting the market today thanks to news its coronavirus treatment received emergency FDA approval. The post REGN Stock: 11 Things for Investors to Know About Regeneron Approval ...

CNBC - 1 week ago

Regeneron will provide the U.S. with 300,000 doses of its newly authorized Covid-19 antibody treatment by early January, CEO Dr. Leonard Schleifer said.

CNBC Television - 1 week ago

Regeneron CEO Dr. Leonard Schleifer on distribution of Covid-19 antibody cocktail

Regeneron CEO Dr. Leonard Schleifer said Monday morning that they'll have 300,000 doses for the U.S. ready by January with 80,000 ready immediately. The company expects to be able to provide 1...

The Motley Fool - 1 week ago

The FDA has granted emergency use authorization to the first COVID-19 treatment option that uses a pair of antibodies to neutralize the novel coronavirus.

Skynews - 1 week ago

An experimental drug used by Donald Trump when he had COVID-19 has received emergency approval by US health authorities.

Market Watch - 1 week ago

Regeneron antibody ‘cocktail' wins emergency-use authorization from FDA

Benzinga - 1 week ago

The U.S. Food and Drug Administration has issued emergency use authorization for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Why It Matters: The two antibodies i...

The Motley Fool - 1 week ago

These three stocks are ready to break out.

Other stocks mentioned: BIIB, PFE
CNBC - 1 week ago

The experimental therapy was given to President Donald Trump when he contracted the coronavirus in October.

Business Insider - 1 week ago

The Food and Drug Administration has allowed for the emergency use of Regeneron's COVID-19 antibody treatment, a step that will make it more widely available to patients. FDA granted an emerge...

PRNewsWire - 1 week ago

TARRYTOWN, N.Y., Nov. 21, 2020 /PRNewswire/ -- First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2 Authorized for r...

InvestorPlace - 2 weeks ago

Nio stock is worth more than Daimler. It sells 1/200th the number of vehicles.

Other stocks mentioned: ATVI, DG
Seeking Alpha - 2 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Virtual London Healthcare Conference (Transcript)

InvestorPlace - 2 weeks ago

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.

Other stocks mentioned: BMY, JNJ, PFE, SNY, XPH, ZTS
Forbes - 2 weeks ago

Pfizer's surprisingly strong initial Covid-19 vaccine efficacy data that came out last week probably marks the beginning of the end of the Covid-19 pandemic. While this is very positive for th...

Other stocks mentioned: GILD, LLY
The Motley Fool - 2 weeks ago

These companies are capitalizing on the market's interest in combating the coronavirus.

Other stocks mentioned: INO
Seeking Alpha - 3 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Managements Presents at Cowen Virtual Presentation Series 2020 IO Next Summit (Transcript)

PRNewsWire - 3 weeks ago

TARRYTOWN, N.Y., Nov. 13, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 3rd Annual HealthCONx Conference at...

Insider Monkey - 3 weeks ago

Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen Focus Growth Composite Portfolio retu...

Investors Business Daily - 3 weeks ago

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared fi...

Other stocks mentioned: ALXN, AMGN, BAYRY, SNY
CNBC Television - 3 weeks ago

Cantor Fitzgerald's Alethia Young on what Coronavirus vaccine news means for the biotech industry

Alethia Young, Head of Health Care Research and Senior Biotech Analyst at Cantor Fitzgerald, joins Worldwide Exchange with her thoughts on how to look at the biotech space, following Pfizer's ...

Other stocks mentioned: GILD, VRTX
Seeking Alpha - 3 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Management at Credit Suisse 29th Annual Virtual Healthcare Conference

The Motley Fool - 3 weeks ago

The future these companies envisioned is much closer than before, thanks to the accelerated development and funding the coronavirus has brought.

Other stocks mentioned: GILD, MRNA
Forbes - 3 weeks ago

Just because a company has a good quarter in the past doesn't mean that their stock prices will continue to rise in the future. That's why our AI models provide an in-depth look at a company's...

Seeking Alpha - 4 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) CEO Dr. Leonard Schleifer on Q3 2020 Results - Earnings Call Transcript

Schaeffers Research - 4 weeks ago

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) are up 0.3% at $588.86 at last check, after the company reported third-quarter earnings of $8.36 per share -- significantly higher th...

Zacks Investment Research - 4 weeks ago

Regeneron (REGN) beats on both earnings and sales in the third quarter of 2020 on strong performances by Eylea and Dupixent. Shares rise in pre-market trading.

The Motley Fool - 4 weeks ago

The big biotech fired on all cylinders in the period.

24/7 Wall Street - 4 weeks ago

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter financial results before the markets opened on Thursday.

Benzinga - 4 weeks ago

  Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 0.5% in pre-market trading after the company reported Q3 results.

Zacks Investment Research - 4 weeks ago

Regeneron (REGN) delivered earnings and revenue surprises of 15.63% and 7.04%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Investors Business Daily - 4 weeks ago

Regeneron earnings and sales beat third-quarter views comfortably for the biotech giant. Shares rose slightly early Thursday.

Market Watch - 4 weeks ago

Regeneron Pharmaceuticals Inc. shares rose 1.6% in premarket trade Thursday, after the drug company blew past estimates for the third quarter and said it has shared data from its Phase 2/3 COV...

PRNewsWire - 4 weeks ago

TARRYTOWN, N.Y., Nov. 5, 2020 /PRNewswire/ -- Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4) Third quarter 2020 EYLEA® U.S. net sales increased 11% to ...

Investors Business Daily - 1 month ago

While the presidential race is undecided awaiting final results from key states, it appears Republicans could retain control of the Senate, and AbbVie stock and other biotech stocks rose. The ...

Other stocks mentioned: ABBV, GILD, JNJ, LLY, MRNA, PFE
Zacks Investment Research - 1 month ago

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CNBC Television - 1 month ago

Jim Cramer lays out how to play health-care stocks after the 2020 election

CNBC's Jim Cramer runs down a list of health-care stocks that could be affected after the 2020 presidential election.

Other stocks mentioned: BMY, CNC, THO, XLV

About REGN

Regeneron Pharmaceuticals, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 2, 1991
CEO
Leonard Schleifer
Employees
8,314
Stock Exchange
NASDAQ
Ticker Symbol
REGN
Full Company Profile

Financial Performance

In 2019, REGN's revenue was $7.86 billion, an increase of 17.18% compared to the previous year's $6.71 billion. Earnings were $2.12 billion, a decrease of -13.44%.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for REGN is 673.13, which is an increase of 36.69% from the latest price.

Price Target
$673.13
(36.69% upside)